globalnews.ca
66%
546
Eli Lilly to resume some coronavirus antibody-drug trials after safety concerns
Eli Lilly & Co on Wednesday said that other trials of its experimental COVID-19 antibody-drug will continue apace after it paused one ongoing trial of the drug, citing safety concerns.The paused trial, which Lilly calls ACTIV-3, focused on hospitalized patients. Lilly said it differed from its other trials in some key respects, including the fact that the patients had more serious illness and were being treated with other drugs, including Gilead Sciences Inc’s remdesivir.Lilly said in a statement that neutralizing antibody drugs such as bamlanivimab, which it is studying in COVID-19 patients, may be less beneficial for hospitalized patients than for those with more mild cases of the disease.